HJV as A Potential Drug Target Or Biomarker for Hemophilia (G148738)

Target Name: HJV

NCBI ID: G148738

Content of Review Report on HJV Target / Biomarker

HJV

HJV as A Potential Drug Target Or Biomarker for Hemophilia

HJV (Hemojuvelin), a protein expressed in the liver, has been identified as a potential drug target or biomarker for the treatment of various diseases, including hemophilia, sickle cell anemia, and thalassemia. Its role in these conditions, as well as its potential utility as a diagnostic marker, makes HJV an intriguing target for researchers.

Hemophilia is a genetic disorder that affects the body's ability to control blood clotting. People with hemophilia have difficulty forming blood clots, which can lead to excessive bleeding or joint pain. Treatment typically involves the use of clotting factors, which can be expensive and may have

Protein Name: Hemojuvelin BMP Co-receptor

Functions: Acts as a bone morphogenetic protein (BMP) coreceptor (PubMed:18976966). Through enhancement of BMP signaling regulates hepcidin (HAMP) expression and regulates iron homeostasis (PubMed:18976966)

The "HJV Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HJV comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets